Novavax, Inc.

NASDAQ:NVAX  
124.57
+21.97 (+21.41%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)7.67B
Current PEN/A
Forward PE N/A
2yr Forward PE 8.65
See more stats
Estimates Current Quarter
Revenue$354.09 Million
Adjusted EPS$0.13
See more estimates
10-Day MA$103.58
50-Day MA$99.08
200-Day MA$73.12
See more pivots

NOVAVAX INC Stock, NASDAQ:NVAX

20 FIRSTFIELD ROAD, GAITHERSBURG, MD 20878
United States of America
Phone: 240-268-2000
Number of Employees: 379

Description

Novavax, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. The company develops respiratory syncytial virus fusion protein nanoparticle vaccine candidate for infants via maternal immunization in Phase III development stage; older adults in Phase II development stage; and children six months to five years of age in Phase I development stage. It also develops Ebola GP vaccine in Phase 1 clinical trial; preclinical programs for Zika virus; and seasonal influenza and a combination respiratory vaccine candidate, as well as other infectious disease vaccine candidates. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.